Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|November 9, 2023
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapyHweixian Leong Penny, Kelly Hainline, Nathaniel Theoharis, et al.
Urologic Oncology|December 5, 2017
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapyXin Chen, Christof Bernemann, Yuri Tolkach, et al.
Cancer Immunology, Immunotherapy : CII|September 25, 2019
The BRCA2 mutation status shapes the immune phenotype of prostate cancerMaximilian Jenzer, Peter Keß, Cathleen Nientiedt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2019
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinomaFrede Donskov, Robert J Motzer, Eric Voog, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell CarcinomaMichael B Atkins, Brian I Rini, Robert J Motzer, et al.
European Urology|September 27, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, et al.
Scientific Reports|May 12, 2018
Genomic features of renal cell carcinoma with venous tumor thrombusGregor Warsow, Daniel Hübschmann, Kortine Kleinheinz, et al.
Nature Communications|June 14, 2016
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneityRouven Hoefflin, Bernd Lahrmann, Gregor Warsow, et al.
Immunotherapy|November 11, 2020
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findingsHorst-Dieter Hummel, Peter Kufer, Carsten Grüllich, et al.
Scientific Reports|November 14, 2018
Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancerClaudia Kesch, Jan-Philipp Radtke, Axel Wintsche, et al.
Pageof 7